Clinical trials: Alzheimer's Disease Psychosis, active
Alzheimer's Disease Psychosis
ACP-204 in Adults With Alzheimer's Disease Psychosis
This is a master protocol for 3 independent, seamlessly enrolling, multicenter, randomized, double-blind, placebo-controlled, parallel-group studies in patients with ADP Substudy 1 (Phase 2) will evaluate efficacy and dose…
- Trial name
- NCT06159673
- Testing
- ACP-204
- Where
- 154 sites in United States, Brazil and 10 more
- Volunteers
- 1,074 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Psychosis Associated With Alzheimer's Disease
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
This is a Phase 3 global, multicenter, 52-week, open-label extension (OLE) rollover study for subjects completing study CN012-0026, CN012-0027 or CN012-0056.
- Trial name
- NCT05980949
- Testing
- KarXT
- Where
- 432 sites in United States, Argentina and 29 more
- Volunteers
- 1,000 people
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Psychosis Associated With Alzheimer's Disease
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
This is a Phase 3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of KarXT in male and female subjects who are aged 55 to 90 years and have mild to severe Alzheimer's…
- Trial name
- NCT06126224
- Testing
- KarXT
- Where
- 157 sites in United States, Belgium and 12 more
- Volunteers
- 500 people
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Psychosis Associated With Alzheimer's Disease
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
ML-007C-MA-221 is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ML-007C-MA in male and female participants aged 55 to 90 years with hallucinations and delusions associated…
- Trial name
- NCT06887192
- Testing
- ML-007C-MA
- Where
- 62 sites in United States, Argentina and 13 more
- Volunteers
- 300 people
- Sponsor
- MapLight Therapeutics
Psychosis Associated With Alzheimer's Disease
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
This is a Phase 3, 38-week, randomized, double-blind, placebo-controlled, multicenter, outpatient study in subjects with psychosis associated with Alzheimer's Disease.
- Trial name
- NCT05511363
- Testing
- KarXT
- Where
- 129 sites in United States, Bulgaria and 11 more
- Volunteers
- 410 people
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Psychosis Associated With Alzheimer's Disease
An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis
ML-007C-MA-222 is a 52-week, flexible-dose, open-label extension study designed to evaluate the long-term safety, tolerability, and effectiveness of ML007C-MA in participants with ADP who have completed the antecedent study (ie…
- Trial name
- NCT07459660
- Testing
- ML-007C-MA
- Where
- 8 sites in United States, Bulgaria and 1 more
- Volunteers
- 210 people
- Sponsor
- MapLight Therapeutics
Alzheimer's Disease Psychosis
ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study
This 52-week, open-label extension study is to evaluate the long-term safety and tolerability of ACP-204 in subjects with ADP.
- Trial name
- NCT06194799
- Testing
- ACP-204
- Where
- 76 sites in United States, Brazil and 10 more
- Volunteers
- 752 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Alzheimer Disease, Psychosis
A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)
The purpose of this study is to evaluate KarXT + KarX-EC as a treatment for psychosis associated with Alzheimer's disease.
- Trial name
- NCT06947941
- Testing
- KarXT, KarX-EC
- Where
- 22 sites in United States, Australia and 3 more
- Volunteers
- 325 people
- Sponsor
- Bristol-Myers Squibb
Alzheimer Disease, Alzheimer Disease With Delusions
Tau Networks in Psychotic Alzheimer's Disease
This research project aims to understand the brain mechanisms behind the manifestation of psychotic symptoms in Alzheimer´s disease (AD), and nature of the unique relationship with tau pathology.
- Conditions
- Alzheimer Disease, Alzheimer Disease With Delusions, Alzheimer Disease With Psychosis
- Trial name
- NCT05847192
- Testing
- [18F]-PI2620 PET scan
- Where
- United States
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- Northwell Health
Schizophrenia, Alzheimer's Disease Psychosis
A Food Effect Study of LY03020 in Healthy Subjects
This is a randomized, open-label, single-dose, two-period, crossover study to assess the food effect on pharmacokinetics (PK) and safety of LY03020 in healthy subjects.
- Trial name
- NCT07292233
- Testing
- LY03020
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Schizophrenia, Alzheimer's Disease Psychosis
A Phase 1 MAD Study to Evaluate the Safety and Tolerability of LY03020
This is a randomized, double-blind, placebo-controlled, ascending multiple oral dose study to assess the safety, tolerability, and pharmacokinetics of LY03020 in Chinese healthy adult subjects and/or subjects with stable…
- Trial name
- NCT07230652
- Testing
- LY03020
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis, Hallucinations and Delusions Associated With Parkinson Disease Psychosis
A Phase 1, MAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LY03017
This is a phase 1，randomized, double-blind, placebo-controlled, MAD study to evaluate the safety, tolerability and pharmacokinetics of oral LPM526000133 Fumarate Capsules (LY03017) in healthy adult subjects
- Conditions
- Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis, Hallucinations and Delusions Associated With Parkinson Disease Psychosis, Negative Symptoms of Schizophrenia
- Trial name
- NCT06980207
- Testing
- LY03017
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Alzheimer's Disease Psychosis, Parkinson Disease Psychosis
Effect of Food and Age on the Pharmacokinetics of LY03017
This study consists of 2 parts. Part A is a randomized, open-label, 2-period, crossover study to evaluate the food effect of LY03017 in healthy adults.
- Conditions
- Alzheimer's Disease Psychosis, Parkinson Disease Psychosis, Negative Symptoms of Schizophrenia
- Trial name
- NCT06793995
- Testing
- LY03017
- Where
- China
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.